Bellevue Group Ag Intra Cellular Therapies, Inc. Transaction History

Bellevue Group Ag

$5.93 Billion
Q3 2024

A detailed history of Bellevue Group Ag transactions in Intra Cellular Therapies, Inc. stock. As of the latest transaction made, Bellevue Group Ag holds 2,485,627 shares of ITCI stock, worth $318 Million. This represents 3.06% of its overall portfolio holdings.

Number of Shares

2,485,627

Previous 2,471,285 0.58%

Holding current value

$318 Million

Previous $169 Million 7.38%

% of portfolio

3.06%

Previous 2.83%

28 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 14, 2024	BUY	$67.99 - $80.84 $975,112 - $1.16 Million	14,342 Added 0.58%	2,485,627 $182 Million
Q2 2024 Aug 14, 2024	SELL	$64.76 - $79.84 $22.5 Million - $27.8 Million	-348,197 Reduced 12.35%	2,471,285 $169 Million
Q1 2024 May 15, 2024	SELL	$64.37 - $75.65 $15.9 Million - $18.7 Million	-246,918 Reduced 8.05%	2,819,482 $195 Million
Q4 2023 Feb 14, 2024	SELL	$46.37 - $73.65 $4.82 Million - $7.65 Million	-103,850 Reduced 3.28%	3,066,400 $220 Million
Q3 2023 Nov 14, 2023	SELL	$52.09 - $64.1 $1.64 Million - $2.02 Million	-31,550 Reduced 0.99%	3,170,250 $165 Million
Q2 2023 Aug 14, 2023	SELL	$54.67 - $66.44 $3.62 Million - $4.4 Million	-66,200 Reduced 2.03%	3,201,800 $203 Million
Q1 2023 May 15, 2023	SELL	$43.8 - $56.99 $3.25 Million - $4.23 Million	-74,236 Reduced 2.22%	3,268,000 $177 Million
Q4 2022 Feb 14, 2023	BUY	$44.07 - $54.45 $571,014 - $705,508	12,957 Added 0.39%	3,342,236 $177 Million
Q3 2022 Nov 14, 2022	SELL	$42.7 - $59.99 $858,270 - $1.21 Million	-20,100 Reduced 0.6%	3,329,279 $155 Million
Q2 2022 Aug 11, 2022	SELL	$43.0 - $65.64 $3.45 Million - $5.27 Million	-80,240 Reduced 2.34%	3,349,379 $191 Million
Q1 2022 May 13, 2022	SELL	$38.74 - $62.09 $7.72 Million - $12.4 Million	-199,300 Reduced 5.49%	3,429,619 $210 Million
Q4 2021 Feb 10, 2022	SELL	$35.2 - $53.42 $5.1 Million - $7.75 Million	-145,000 Reduced 3.84%	3,628,919 $190 Million
Q3 2021 Nov 12, 2021	BUY	$28.72 - $42.49 $4.71 Million - $6.97 Million	164,000 Added 4.54%	3,773,919 $141 Million
Q2 2021 Aug 12, 2021	SELL	$29.3 - $44.5 $1.47 Million - $2.23 Million	-50,000 Reduced 1.37%	3,609,919 $147 Million
Q4 2020 Feb 16, 2021	BUY	$23.34 - $32.22 $1.87 Million - $2.58 Million	80,000 Added 2.23%	3,659,919 $116 Million
Q3 2020 Nov 16, 2020	SELL	$17.61 - $31.86 $3.52 Million - $6.37 Million	-200,000 Reduced 5.29%	3,579,919 $91.9 Million
Q2 2020 Aug 13, 2020	BUY	$14.35 - $26.64 $690,235 - $1.28 Million	48,100 Added 1.29%	3,779,919 $97 Million
Q1 2020 May 14, 2020	BUY	$12.31 - $33.12 $16.8 Million - $45.2 Million	1,365,819 Added 57.73%	3,731,819 $57.4 Million
Q4 2019 Feb 14, 2020	SELL	$7.26 - $38.49 $1.62 Million - $8.58 Million	-222,990 Reduced 8.61%	2,366,000 $81.2 Million
Q3 2019 Nov 14, 2019	BUY	$7.47 - $14.03 $2.57 Million - $4.82 Million	343,490 Added 15.3%	2,588,990 $19.3 Million
Q2 2019 Aug 14, 2019	BUY	$10.65 - $14.29 $23.9 Million - $32.1 Million	2,245,500 New	2,245,500 $29.1 Million
Q1 2019 May 15, 2019	SELL	$10.9 - $14.09 $573,340 - $741,134	-52,600 Closed	0 $0
Q4 2018 Feb 12, 2019	SELL	$10.36 - $20.96 $20,720 - $41,920	-2,000 Reduced 3.66%	52,600 $599,000
Q3 2018 Nov 13, 2018	SELL	$17.77 - $22.9 $449,581 - $579,370	-25,300 Reduced 31.66%	54,600 $1.19 Million
Q2 2018 Aug 07, 2018	SELL	$17.33 - $23.4 $192,362 - $259,739	-11,100 Reduced 12.2%	79,900 $1.41 Million
Q1 2018 May 09, 2018	SELL	$15.16 - $25.49 $22,740 - $38,235	-1,500 Reduced 1.62%	91,000 $1.92 Million
Q4 2017 Feb 14, 2018	BUY	$14.27 - $16.79 $749,175 - $881,475	52,500 Added 131.25%	92,500 $1.34 Million
Q2 2017 Aug 14, 2017	BUY	N/A	40,000	40,000 $497,000

Others Institutions Holding ITCI

# of Institutions

390

Shares Held

88.9M

Call Options Held

202K

Put Options Held

114K

View Full List

About Intra-Cellular Therapies, Inc.

Ticker ITCI
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 94,401,696
Market Cap $12.1B
Description
Intra-Cellular Therapies, Inc., a biopharmaceutical company, develops novel drugs for the treatment of neuropsychiatric and neurologic diseases by targeting intracellular signaling mechanisms within the central nervous system in the United States. The company offers CAPLYTA for the treatment of schizophrenia in adults. It is also involved in dev...

More about ITCI

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Bellevue Group Ag, based on Form 13F filings with the SEC.

News

Stay updated on Bellevue Group Ag with notifications on news.

Account

Bellevue Group Ag Intra Cellular Therapies, Inc. Transaction History